.png){kind=tracking}
India's Rapid Diagnostics Market Poised for $909 Million by 2030, Driven by Infectious Disease Burden and Public Health
The India Rapid Diagnostics Market is experiencing significant expansion, primarily fueled by the nation's substantial burden of infectious diseases, escalating public health initiatives, and the increasing demand for accessible and affordable diagnostic solutions, especially at the point-of-care. Rapid medical diagnostic kits are indispensable tools for early disease detection, crucial for timely treatment, effective disease management, and public health surveillance. The rapid medical diagnostic kits market in India was valued at US$ 657.9 million in 2023 and is expected to reach a projected revenue of US$ 909.3 million by 2030, demonstrating a Compound Annual Growth Rate (CAGR) of 4.7% from 2024 to 2030. This growth highlights India's commitment to enhancing its diagnostic infrastructure.
The market's trajectory is deeply intertwined with India's public health priorities, particularly in combating endemic and emerging infectious threats.
Key Market Drivers and Trends:
High Burden of Infectious Diseases: India faces a significant and diverse burden of infectious diseases, including Tuberculosis (TB), Malaria, Dengue, Chikungunya, Viral Hepatitis, Zika, and various zoonotic diseases. For instance, India reported 2.6 million TB cases last year, and as of May 2025, had recorded 12,043 dengue cases and 30,876 chikungunya cases this year. This necessitates widespread and rapid testing capabilities, directly driving the demand for RDTs across various applications like infectious disease testing.
Growing Public Health Initiatives and Government Support: The Indian government and health agencies like ICMR are actively promoting and investing in diagnostic capabilities. The health ministry may task ICMR with developing advanced technologies and diagnostics for infectious diseases to augment preparedness against future pandemics. Plans include setting up 60 accredited Medical Device Testing Laboratories (MDTLs) and biobanks across the country. These initiatives enhance the infrastructure for RDTs and facilitate their adoption.
Expansion of Point-of-Care (POC) Testing: Rapid diagnostic kits are ideal for POC settings, allowing for quick results (e.g., 30-60 minutes for TrueNat COVID-19 tests) with minimal infrastructure and training. This is crucial for reaching remote and underserved areas. The adoption of technologies like TrueNat and CBNAAT has been pivotal in expanding COVID-19 testing to district facilities and primary health centers, significantly boosting testing rates.
Increasing Awareness Campaigns and Accessibility: Leading market players and public health bodies are conducting awareness campaigns to educate the public about various diseases and the importance of early diagnosis. For example, Abbott's partnership with the Odisha government and Malaria No More to curb malaria includes providing expertise and technology. This increased awareness drives the demand for readily available diagnostic tools, including Over-The-Counter (OTC) RDTs. The OTC RDT segment was the largest revenue-generating product in 2023 (62.75% share) and is projected to be the fastest-growing.
Technological Advancements and Indigenous Development: Indian researchers and companies are actively involved in developing innovative and affordable rapid diagnostic technologies. For instance, IIT Guwahati researchers developed a new paper-based test kit for malaria in June 2019. This focus on indigenous R&D makes rapid tests more accessible and tailored to local needs.
Healthcare Infrastructure Expansion: The overall expansion of healthcare infrastructure, including new hospitals, clinics, and diagnostic laboratories, particularly in tier 2 and tier 3 cities, contributes to the increased demand for rapid diagnostic kits for routine and emergency testing. Hospitals & clinics were a dominant end-use segment in 2023.
Combating Antimicrobial Resistance (AMR): With AMR directly causing an estimated 297,000 deaths in India in 2019, and 142,660 patients with AMR reported in government facilities in 2023, rapid diagnostics are becoming critical for quickly identifying pathogens and guiding targeted treatment, thus reducing the misuse of antibiotics.
Despite challenges such as ensuring the quality and reliability of all available rapid diagnostic kits, managing cold chain logistics for reagent stability in diverse climates, and the need for continuous training of healthcare personnel in remote areas, the India Rapid Diagnostics Market is on a robust growth path. The combination of a high disease burden, proactive government initiatives, and an increasing focus on accessible and affordable healthcare solidifies its vital role in improving public health outcomes across the nation.
About Market Research Future (MRFR)
Market Research Future (MRFR) is a global market research firm that provides comprehensive insights into market trends, drivers, challenges, and opportunities. We offer a broad range of market intelligence reports and consulting services to help businesses and enterprises in various industries make informed decisions.
Media Contact:
Market Research Future (MRFR)
Phone: +1-646-845-9312
Email: contact@marketresearchfuture.com
Website: marketresearchfuture
